{}
Ester, diagnosed with ATTR amyloidosis, Netherlands
Alnylam's Norton, Massachusetts (U.S.) Manufacturing Facility
Employees at Alnylam's U.S. Headquarters
Our News
2025 Year in Review & Look Ahead: CEO Yvonne Greenstreet on a Transformational Year for Alnylam
April 7, 2026
Yvonne Greenstreet, MD, MBA, OBE
CEO, Alnylam Pharmaceuticals
2025 was a transformational year for Alnylam, marked by exceptional progress across the business and the remarkable start to the launch of AMVUTTRA® (vutrisiran) for patients with ATTR cardiomyopathy. The AMVUTTRA launch has fundamentally changed our trajectory—accelerating our growth, enabling greater investment in our next wave of medicines, and opening a new era of unprecedented opportunity for the company.
AMVUTTRA has the potential to become the new standard of care in the large and growing TTR market. Its increasing use by both newly diagnosed patients and those switching from other therapies underscores its compelling clinical profile and reflects strong engagement from physicians, patients, and payers. Outside the U.S., regulatory approvals in Japan, the EU, and numerous additional markets will enable us to deliver AMVUTTRA to patients across the globe.
I'm pleased to note some highlights from last year that underscore the strong progress we made across our business below and invite you to read more in our 2025 annual report.
Robust Commercial Performance: The AMVUTTRA launch drove our robust commercial performance, with combined net product revenue rising to $2.987 billion, 81 percent greater than in 2024. TTR Franchise revenue doubled from the prior year, with sales of AMVUTTRA and ONPATTRO®(patisiran) generating $2.487 billion—or more than $800 million above our original 2025 guidance. Our Rare Disease business continued its steady growth, with sales of GIVLAARI®(givosiran) and OXLUMO® (lumasiran) increasing 18 percent year-over-year to $500 million.
Leqvio® (inclisiran), an RNAi therapeutic discovered and developed by Alnylam, has become one of our partner Novartis’ top-selling medicines, while partner Sanofi received FDA approval in 2025 for Qfitlia® (fitusiran), another Alnylam-discovered RNAi medicine, highlighting the power of our RNAi platform and the generational technology we are advancing.
Ester, diagnosed with ATTR amyloidosis, NetherlandsWe ended 2025 with a cash and investment balance of approximately $2.9 billion and achieved GAAP profitability for the first time, a pivotal milestone that reflects our strong growth and financial discipline. Sustaining profitability will allow us to fund the investment we plan in our burgeoning pipeline of new medicines that may have the potential to prevent, halt, or reverse disease. In doing so, we are advancing the vision that has guided Alnylam since its founding: realizing RNA interference (RNAi) as a new class of gene silencing medicines capable of transforming human health.
Growth Through Innovation: In 2025, we made significant progress across our pipeline, which includes a number of medicines in development with multi-billion-dollar revenue potential.
- We initiated three Phase 3 studies: the TRITON-PN and TRITON-CM studies of our next-generation TTR silencer nucresiran, and the ZENITH cardiovascular outcomes trial of zilebesiran for hypertension, a study that underscores our growing commitment to cardiovascular disease.
- Within neuroscience, we are advancing our programs with urgency and conviction given the enormous unmet medical need in this field. Mivelsiran is designed to prevent amyloid deposition in the brain and is being evaluated in a Phase 2 study in cerebral amyloid angiopathy, with a Phase 2 study in Alzheimer’s disease planned to begin in the first half of 2026. We are also advancing ALN-HTT02 in a Phase 1 study for Huntington’s disease, with initial results expected this year.
- Within hematology, we are focused on advancing ALN-6400, which holds exciting potential to address a wide range of bleeding disorders, with a Phase 2 study underway now for a lead indication, hereditary hemorrhagic telangiectasia.
- In metabolic diseases, we see a compelling opportunity to address significant gaps in treatment left by GLP-1 medicines. ALN-4324 holds the potential to be a novel insulin sensitizer for people with type 2 diabetes, while ALN-2232 is our first candidate for obesity and weight management, with the potential to lead to durable and fat-specific weight loss. ALN-2232 also represents another first for Alnylam: delivery of an investigational RNAi therapeutic to adipose tissue.
Alnylam's Norton, Massachusetts (U.S.) Manufacturing FacilityScaling for Growth: To bring the remarkable advances we are making in the clinic to the patients who need them, we continue to focus on scaling the company. In 2025, we launched a critical expansion of our flagship Norton manufacturing site, to advance what is poised to become the industry’s first fully dedicated, proprietary siRNA enzymatic ligation manufacturing facility, as we implement our new siRELIS™ platform, a novel approach to producing RNAi therapeutics that is expected to meaningfully expand capacity and significantly reduce production costs.
Our People and Culture: As we build for the future, we remain focused on sustaining a culture that supports and attracts great people. Alnylam was widely recognized again last year as an exceptional place to work, including by USA Today, Science Magazine, Fast Company, and The Boston Globe. We were also named again to Newsweek’s list of America’s Most Socially Responsible Companies and improved our already-strong ESG ratings, reflecting the deep commitment highlighted in our annual Corporate Responsibility Report.
Employees at Alnylam's U.S. HeadquartersSetting Bold Goals: In 2025, we marked the conclusion of a pivotal chapter in our history, declaring victory on our Alnylam P5x25 goals, which guided our strategy for the past five years. We met or exceeded each of these goals, delivering six approved medicines to approximately 500,000 patients; returning a five-year compound annual revenue growth rate of approximately 50 percent; dramatically expanding our pipeline; and achieving profitability.
Continuing our long heritage of setting and achieving bold five-year goals, we have launched our Alnylam 2030 strategy, which reflects our enormous ambition for the company and commits us to achieving market leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility.
We are building an extraordinary company with the potential to help millions of people. In the transformational year just concluded, we firmly established Alnylam among the top biotechnology companies in the world. Now we intend to continue our ascent, advancing our science, expanding our reach, and delivering even greater impact for patients.
Yvonne Greenstreet, MD, MBА, ОВЕ
Chief Executive Officer
FOLLOW US
